123 related articles for article (PubMed ID: 31634190)
1. Immune checkpoint inhibitors in people living with HIV: what about anti-HIV effects?
Abbar B; Baron M; Katlama C; Marcelin AG; Veyri M; Autran B; Guihot A; Spano JP
AIDS; 2020 Feb; 34(2):167-175. PubMed ID: 31634190
[TBL] [Abstract][Full Text] [Related]
2. Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pretreatment plasma virus load.
Oxenius A; Price DA; Dawson SJ; Günthard HF; Fischer M; Perrin L; Ramirez E; Fagard C; Hirschel B; Scullard G; Weber JN; McLean AR; Phillips RE;
AIDS; 2002 Nov; 16(17):2317-22. PubMed ID: 12441804
[TBL] [Abstract][Full Text] [Related]
3. Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study.
Sgadari C; Monini P; Tripiciano A; Picconi O; Casabianca A; Orlandi C; Moretti S; Francavilla V; Arancio A; Paniccia G; Campagna M; Bellino S; Meschiari M; Nozza S; Sighinolfi L; Latini A; Muscatello A; Saracino A; Di Pietro M; Galli M; Cafaro A; Magnani M; Ensoli F; Ensoli B
Front Immunol; 2019; 10():233. PubMed ID: 30815001
[No Abstract] [Full Text] [Related]
4. Magnitude and complexity of rectal mucosa HIV-1-specific CD8+ T-cell responses during chronic infection reflect clinical status.
Critchfield JW; Young DH; Hayes TL; Braun JV; Garcia JC; Pollard RB; Shacklett BL
PLoS One; 2008; 3(10):e3577. PubMed ID: 18974782
[TBL] [Abstract][Full Text] [Related]
5. CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients.
Lu W; Mehraj V; Vyboh K; Cao W; Li T; Routy JP
J Int AIDS Soc; 2015; 18(1):20052. PubMed ID: 26130226
[TBL] [Abstract][Full Text] [Related]
6. Increased soluble Fas in HIV-infected hemophilia patients with CD4+ and CD8+ cell count increases and viral load and immune complex decreases.
Daniel V; Süsal C; Weimer R; Zimmermann R; Huth-Kühne A; Opelz G
AIDS Res Hum Retroviruses; 2001 Mar; 17(4):329-35. PubMed ID: 11242519
[TBL] [Abstract][Full Text] [Related]
7. Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.
Hey-Cunningham WJ; Murray JM; Natarajan V; Amin J; Moore CL; Emery S; Cooper DA; Zaunders J; Kelleher AD; Koelsch KK;
AIDS; 2015 May; 29(8):911-9. PubMed ID: 25730509
[TBL] [Abstract][Full Text] [Related]
8. Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology.
Mylvaganam G; Yanez AG; Maus M; Walker BD
Front Immunol; 2019; 10():2109. PubMed ID: 31552045
[TBL] [Abstract][Full Text] [Related]
9. Recovery of effective HIV-specific CD4+ T-cell activity following antiretroviral therapy in paediatric infection requires sustained suppression of viraemia.
Adland E; Mori L; Laker L; Csala A; Muenchhoff M; Swordy A; Mori M; Matthews P; Tudor-Williams G; Jooste P; Goulder P
AIDS; 2018 Jul; 32(11):1413-1422. PubMed ID: 29734220
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.
Harrer T; Plettenberg A; Arastéh K; Van Lunzen J; Fätkenheuer G; Jaeger H; Janssens M; Burny W; Collard A; Roman F; Loeliger A; Koutsoukos M; Bourguignon P; Lavreys L; Voss G
Vaccine; 2014 May; 32(22):2657-65. PubMed ID: 24144472
[TBL] [Abstract][Full Text] [Related]
11. [HIV and cancer: Update 2020].
Abbar B; Veyri M; Solas C; Poizot-Martin I; Spano JP
Bull Cancer; 2020 Jan; 107(1):21-29. PubMed ID: 31980144
[TBL] [Abstract][Full Text] [Related]
12. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial.
Nakanjako D; Ssinabulya I; Nabatanzi R; Bayigga L; Kiragga A; Joloba M; Kaleebu P; Kambugu AD; Kamya MR; Sekaly R; Elliott A; Mayanja-Kizza H
Trop Med Int Health; 2015 Mar; 20(3):380-90. PubMed ID: 25441397
[TBL] [Abstract][Full Text] [Related]
14. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
[TBL] [Abstract][Full Text] [Related]
15. CD4/CD8 Ratio Predicts Yellow Fever Vaccine-Induced Antibody Titers in Virologically Suppressed HIV-Infected Patients.
Avelino-Silva VI; Miyaji KT; Mathias A; Costa DA; de Carvalho Dias JZ; Lima SB; Simoes M; Freire MS; Caiaffa-Filho HH; Hong MA; Lopes MH; Sartori AM; Kallas EG
J Acquir Immune Defic Syndr; 2016 Feb; 71(2):189-95. PubMed ID: 26361176
[TBL] [Abstract][Full Text] [Related]
16. Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial.
Leth S; Schleimann MH; Nissen SK; Højen JF; Olesen R; Graversen ME; Jørgensen S; Kjær AS; Denton PW; Mørk A; Sommerfelt MA; Krogsgaard K; Østergaard L; Rasmussen TA; Tolstrup M; Søgaard OS
Lancet HIV; 2016 Oct; 3(10):e463-72. PubMed ID: 27658863
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis A vaccination and immunological parameters in HIV-infected patients.
Kourkounti S; Papaizos V; Leuow K; Kordosis T; Antoniou C
Viral Immunol; 2013 Oct; 26(5):357-63. PubMed ID: 24044625
[TBL] [Abstract][Full Text] [Related]
18. The immunomodulatory nutritional intervention NR100157 reduced CD4+ T-cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study).
Cahn P; Ruxrungtham K; Gazzard B; Diaz RS; Gori A; Kotler DP; Vriesema A; Georgiou NA; Garssen J; Clerici M; Lange JM;
Clin Infect Dis; 2013 Jul; 57(1):139-46. PubMed ID: 23511299
[TBL] [Abstract][Full Text] [Related]
19. A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy.
Tung FY; Tung JK; Pallikkuth S; Pahwa S; Fischl MA
Vaccine; 2016 Apr; 34(19):2225-32. PubMed ID: 27002500
[TBL] [Abstract][Full Text] [Related]
20. HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: comparison of statistical methods for measurement.
Lubaki NM; Shepherd ME; Brookmeyer RS; Hon H; Quinn TC; Kashamuka M; Johnson M; Gottle R; Devers J; Lederman HM; Bollinger RC
J Acquir Immune Defic Syndr; 1999 Sep; 22(1):19-30. PubMed ID: 10534143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
